Search results for "From ACP Journal Club"


 
Results 41 - 50 of about 131 for "From ACP Journal Club".
Sort by: Relevance | Newest | Oldest

In abstinent adults with type 2 diabetes, a daily glass of wine (vs mineral water) improved cardiometabolic factors

Drinking red wine, rather than mineral water, with dinner every night for 2 years was associated with improvements in cholesterol markers in patients in Israel. A group assigned to white wine did not show significant differences on these markers from the water group.
https://diabetes.acponline.org/archives/2016/03/11/6.htm
11 Mar 2016

Canagliflozin reduced kidney failure and CV events at 2.6 years in type 2 diabetes with chronic kidney disease

Sodium–glucose cotransporter 2 inhibitors appear to be a promising treatment option for patients with diabetes and chronic kidney disease, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2019/09/13/6.htm
13 Sep 2019

Review: Viscous fiber reduces HbA1c, fasting glucose, and insulin resistance in type 2 diabetes

An ACP Journal Club commentary recommends advising patients with type 2 diabetes who don't smoke and who take metformin to also consider increasing their soluble fiber intake by more than 10 g/d.
https://diabetes.acponline.org/archives/2019/06/14/6.htm
14 Jun 2019

Review: Adding a DPP-4 inhibitor to an SGLT-2 inhibitor reduces genital, but not genitourinary, tract infections

The authors of an accompanying ACP Journal Club commentary noted that although the risk for bias in the five reviewed studies was reportedly low, the results were imprecise and inconsistent, leaving little confidence in the evidence of an apparent reduction in infection risk with dipeptidyl peptidase-4 (DPP-4) inhibitors.
https://diabetes.acponline.org/archives/2018/04/13/7.htm
13 Apr 2018

In patients with type 2 diabetes and CV disease, empagliflozin reduced a composite of CV events at 3.1 years

An industry-funded trial found that those who took empagliflozin had lower rates of mortality, including from cardiovascular (CV) events, than those on placebo. A commentary in ACP Journal Club called the trial results fascinating but said they are not yet sufficient to change practice.
https://diabetes.acponline.org/archives/2016/02/12/5.htm
12 Feb 2016

In type 2 diabetes, SGLT2 inhibitors reduce all-cause, but not cardiovascular, mortality vs. GLP-1 RAs

A meta-analysis identified relative benefits of sodium–glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) based on individual cardiovascular and renal risks.
https://diabetes.acponline.org/archives/2021/06/11/8.htm
11 Jun 2021

Studies analyze amputation rates with sodium–glucose cotransporter-2 inhibitors

An ACP Journal Club commentary looked at studies on the effects of canagliflozin in patients with cardiovascular disease and dapagliflozin in patients with peripheral artery disease, concluding that amputation risks are small enough that they needn't play a major role in prescribing decisions.
https://diabetes.acponline.org/archives/2021/02/12/7.htm
12 Feb 2021

In type 2 diabetes with periodontitis, intensive periodontitis treatment improved glycemic control at 1 year

Putting these findings into practice may require incorporating dental professionals into diabetes care teams and training clinicians who treat patients with diabetes to recognize and assess periodontal disease and make appropriate referrals, the ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2019/05/10/8.htm
10 May 2019

In stable CAD with type 2 diabetes, adding ticagrelor to aspirin reduced CV events but increased major bleeding

Although an industry-funded trial found little net benefit overall from adding ticagrelor to aspirin, it's possible that some patients with higher ischemic risk and low bleeding risk could benefit, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2020/02/14/6.htm
14 Feb 2020

In diabetes with no CVD, aspirin reduced serious vascular events but increased major bleeding at 7.4 years

The results of a recent trial of aspirin for cardiovascular disease (CVD) prevention in diabetes challenge current guidelines and the opinion of many clinicians of the net benefit of the drug, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2019/01/11/6.htm
11 Jan 2019

Result Page: Prev   1   2   3   4   5   6   7   8   9   10   Next